Ablynx Collaborates with Merck to Develop Therapeutic Nanobody Candidates - Gilde Healthcare

Ablynx Collaborates with Merck to Develop Therapeutic Nanobody Candidates

October 2, 2012

GHENT, Belgium – Ablynx [Euronext Brussels: ABLX] today announced a collaboration with Merck & Co., Inc., through a subsidiary, to develop and commercialise Nanobody® candidates directed towards a voltage gated ion channel with the option to develop and commercialise a Nanobody to a second target. Merck is known as MSD outside the United States and Canada.

Under the terms of the agreement, Merck gains exclusive global rights to Nanobodies against the selected target, with an option for similar rights to a second target. Upon signing, Merck will pay Ablynx a €6.5 million upfront payment and a €2 million fee for research funding. In addition, Ablynx will be eligible to receive up to €448 million in research, regulatory and commercial milestone payments associated with the progress of multiple candidates as well as tiered royalties on any products derived from the collaboration. Ablynx will be responsible for the discovery of Nanobody candidates and Merck will be responsible for the research, development, manufacturing and commercialisation of any Nanobody product resulting from the collaboration.

Dr Edwin Moses, Chairman and CEO of Ablynx said:

“We are delighted to initiate this collaboration with Merck in the area of ion channels where to date monoclonal antibodies have demonstrated little success. Due to the formatting flexibility of Nanobodies, we are able to combine antibody-like selectivity and multi-specificity in one molecule, making them ideal candidates for ion channel modulators. This agreement reflects the potential power of the Nanobody platform and the considerable success we have had to date with seven Nanobody programmes at the clinical development stage.”

“We are excited to be working with Ablynx to evaluate the potential of the Nanobody technology directed towards this challenging ion channel target,”

said Richard Hargreaves, Ph.D., Vice President and Head of Neuroscience Discovery Research at Merck.

About Ablynx’ expertise in ion channels

Ablynx has already demonstrated modulation of ion channel activity in electrophysiology assays and has identified functional Nanobodies against both voltage-gated and ligand-gated ion channels. Nanobodies can be generated to have either an agonistic (enhancing) or antagonistic (blocking) effect.

About ion channels

The physiological importance of ion channels is underlined by their involvement in a wide range of conditions including neurological disorders, hypertension, diabetes, cancer and arrhythmia. Ion channels represent highly valuable therapeutic targets which are currently modulated by a range of small molecule drugs. In 2011, sales of the top 20 best-selling ion channel drugs amounted nearly $14 billion.[1] Today, there are no approved antibody-based drugs that target ion channels.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline http://www.ablynx.com/en/research-development/pipeline/ and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis, and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

Gilde Healthcare invests in German precision surgical instruments contract manufacturer Koscher & Würtz

The acquisition of Koscher & Würtz represents a major step for Gilde Healthcare in forming a market leading instrument contract manufacturing group, following its initial investment in Chr. Diener, less than 18 months ago. Koscher...
November 20, 2023

Gilde Healthcare closes new Venture&Growth fund at €740 million hard cap

Gilde Healthcare Venture&Growth VI closes at its hard cap with €740 million from a balanced mix of international investors Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by...
November 15, 2023

Gilde Healthcare company SpliceBio enters $216 million Gene Therapy collaboration with Spark Therapeutics

SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy...
October 17, 2023